
Immutep Limited IMMP
€ 0.32
-2.96%
Geschäftsbericht 2025
hinzugefügt 21.03.2026
Immutep Limited Gesamtes Eigenkapital 2011-2026 | IMMP
Gesamtes Eigenkapital Jährlich Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 33.3 M | 24.4 M | 33.5 M | 26.5 M | 35.3 M | - | - | - | - | - |
Alle Zahlen in AUD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 35.3 M | 24.4 M | 30.6 M |
Gesamtes Eigenkapital Vierteljährlich Immutep Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 73.3 M | - | - | - | 33.3 M | - | - | - | 24.4 M | - | - | - | 33.5 M | - | - | - | 26.5 M | - | - | - | 35.3 M | - | - | - | 24.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in AUD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 73.3 M | 24.4 M | 35.9 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Keros Therapeutics
KROS
|
303 M | $ 11.08 | -1.47 % | $ 412 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
884 M | $ 216.97 | -0.5 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.25 | 0.1 % | $ 900 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.67 | 10.54 % | $ 7.67 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.4 | -0.36 % | $ 357 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
19 M | $ 2.63 | - | $ 16.5 M | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
830 M | $ 199.63 | -0.36 % | $ 3.65 B | ||
|
Longeveron
LGVN
|
5.68 M | $ 0.9 | -5.5 % | $ 15.8 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.3 | -2.83 % | $ 824 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
3.99 M | $ 2.65 | -0.38 % | $ 5.08 M | ||
|
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | ||
|
Harmony Biosciences Holdings
HRMY
|
870 M | $ 27.05 | -1.99 % | $ 1.56 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M |